NCT06371807 - Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2024

Primary Completion Date

July 31, 2025

Study Completion Date

December 31, 2026

Conditions

Early Breast CancerTriple Negative Breast Cancer

Interventions

DRUG

Pembrolizumab injection

(KXCb - PA\[E\]C) vs (KPA\[E\]C - KXCb) Pembrolizumab (K) + paclitaxel (X) + carboplatin (Cb) followed by pembrolizumab + doxorubicin or epirubicin (A or E) + cyclophosphamide (C) followed by pembrolizumab in the adjuvant setting vs Pembrolizumab + doxorubicin or epirubicin (A or E) + cyclophosphamide (C) followed by pembrolizumab (K) + paclitaxel (X) + carboplatin (Cb) followed by pembrolizumab in the adjuvant setting

Trial Locations (3)

1400-038

Fundaçao Champalimaud, Avenida Brasilia,, Lisbon

1649-028

Centro Hospitalar Universitário Lisboa Norte E.P.E, Lisbon

4200-072

Instituto Português de Oncologia Francisco Gentil, E.P.E, Porto

All Listed Sponsors

lead

Fundacao Champalimaud

OTHER